Bristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies
Xencor Inc (NASDAQ: XNCR has entered into a technology license agreement with Bristol-Myers Squibb Co (NYSE: BMY), under which BMY will have non-exclusive access to Xencor's Xtend Fc technology to extend the half-life of a novel antibody combination therapy for COVID-19.
Under the terms of the agreement, Bristol Myers Squibb will have sole responsibility for supporting and advancing the research, development, regulatory and commercial activities for SARS-CoV-2 mAb Duo.
Xencor is eligible to receive royalties from net sales of products, including these antibodies.
"Xencor's Xtend Fc domains have been incorporated into more than a dozen clinical-stage programs or commercialized medicines, including two programs under investigation for the treatment of COVID-19 and five for other infectious diseases," said Bassil Dahiyat, President & CEO of Xencor.
Price Action: XNCR shares are down 0.31% at $39.11 during the market session on the last check Tuesday.
See more from Benzinga
Bristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate Zeposia
Bristol Myers Wins Positive Opinion From EU For Opdivo/Yervoy Combo In Colorectal Cancer
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.